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Abstract: Compelling evidence indicates that protein kinase CK2 plays an important role in
many steps of cancer initiation and progression, therefore, the development of effective and
cell-permeable inhibitors targeting this kinase has become an important objective for the treatment of
a variety of cancer types including glioblastoma. We have recently identified 1,3-dichloro-6-[(E)-((4-
methoxyphenyl)imino)methyl]dibenzo(b,d)furan-2,7-diol (D11) as a potent and selective inhibitor of
protein kinase CK2. In this study, we have further characterized this compound and demonstrated
that it suppresses CK2 kinase activity by mixed type inhibition (KI 7.7 nM, KI′ 42 nM). Incubation
of glioblastoma cells with D11 induces cell death and upon hypoxia the compound leads to HIF-1α
destabilization. The analysis of differential mRNA expression related to human hypoxia signaling
pathway revealed that D11-mediated inhibition of CK2 caused strong down-regulation of genes
associated with the hypoxia response including ANGPTL4, CA9, IGFBP3, MMP9, SLC2A1 and VEGFA.
Taken together, the results reported here support the notion that including D11 in future treatment
regimens might turn out to be a promising strategy to target tumor hypoxia to overcome resistance to
radio- and chemotherapy.
Keywords: CK2; D11; HIF-1α; glioblastoma cells; gene expression profiling
1. Introduction
Glioblastoma is the most common primary tumor of the central nervous system and one of the
most lethal types of human cancer. Patients with newly diagnosed glioblastoma have a median survival
of approximately one year and respond poorly to all treatment modalities [1,2]. A comprehensive
characterization of over 200 samples from patients diagnosed with glioblastoma has provided a detailed
map of the many genomic and transcriptional alterations that occur in this type of malignancy and that
contribute to its aggressive character [3–5]. Overexpression of the epidermal growth factor receptor
(EGFR), which is linked to aberrant phosphoinositide 3-kinase (PI3K/AKT) pathway, is among the
most frequent aberrations. However, cancer genomic studies have revealed that multiple components
of the aforementioned pathway are frequently targeted by germline or somatic mutations contributing
to tumor resistance to both radiotherapy and chemotherapy [5]. In this respect, glioblastoma has one of
the highest incidence rates of phosphatase and tensin homolog (PTEN) mutation that has been strongly
associated with a selective advantage for tumor expansion [6]. Loss of PTEN expression results in
hyperactivation of the pro-survival PI3K/AKT pathway and increased resistance to apoptosis [7].
All tumors require active angiogenesis for expansion and glioblastoma is a highly vascularized
type of cancer exhibiting increased expression of many pro-angiogenic genes such as vascular
endothelial growth factor (VEGF) and fibroblast growth factor (FGF) [8]. Despite the extended
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vascularization, glioblastoma is highly heterogeneous and dominated by areas with low oxygen
supply and compromised vascular integrity [9].
One of the major events in hypoxia adaptation is the induction of the hypoxia inducible factor
1 (HIF-1α) a transcription factor that regulates multiple intracellular processes including glycolysis,
angiogenesis, immortalization, tissue invasion and metastasis, genetic instability and cell death
(reviewed in [10]). From a therapeutic standpoint, hypoxia, genomic and tumor-tissue heterogeneity
are a major clinical hurdle emphasizing the importance to set up tailored therapeutic strategies able to
tackle the heterogeneous nature of brain cancer. Up-regulation of HIF-1α leads to a rapid response in
hypoxic cells. Thus, identification of compounds able to block HIF-1α or its target genes for inhibiting
tumor growth has become a top priority in many research laboratories.
We have recently identified 1,3-dichloro-6-[(E)-((4-methoxyphenyl)imino)methyl]dibenzo-
(b,d)furan-2,7-diol (hereafter referred to as D11) as a potent and selective inhibitor of protein kinase
CK2 [11,12]. CK2 is a highly conserved and constitutively active serine/threonine protein kinase
whose expression levels have been found invariably elevated in highly proliferating cells. CK2 is
implicated in multiple cellular functions as well as in cell transformation and tumorigenesis [13–17].
Recent data from our laboratory have demonstrated that D11 treatment induces apoptosis in brain and
pancreatic cancer cells through a mechanism involving down-regulation of the PI3K/AKT and NF-κB
signaling cascades [12]. Interestingly, inhibition of CK2 has been shown to decrease HIF-1α activity
under hypoxia through elevated p53 expression levels [18].
Since the high incidence of PTEN mutation observed in glioblastoma cells has been strongly
associated with stimulation of HIF-1α-mediated gene expression and increased apoptotic resistance [6],
we investigated whether D11-mediated cell death induction was accompanied by destabilization
and/or inhibition of HIF-1α transcription factor and, if so, how does D11 influence the expression of
genes regulated by HIF-1α under hypoxic conditions. Results shown in this study suggest that D11
may exert anti-tumor activity by negatively affecting cellular pathways that are normally up-regulated
under low oxygen tension and warrant in vivo studies for endorsing its efficacy in the treatment of
multi-drug resistant human cancers.
2. Results
2.1. D11 is A CK2 Inhibitor That Leads to Cell Death in Glioblastoma Cells
D11 was identified employing the catalytic α-subunit of protein kinase CK2 following a screening
of a small-molecule compound library of the Diversity Set III under the drug discovery and therapeutic
program (DTP) of the National Cancer Institute (NCI, Rockville, MD, USA, [11]). Kinetic measurements
revealed that this compound inhibits the catalytic activity of both CK2α and CK2 holoenzyme in the
low nM range [11]. Furthermore, the screening of 354 protein kinases revealed that D11 is a selective
inhibitor of CK2. By setting the threshold for inhibition to >98%, only three protein kinases were found
inhibited to an extent observed with CK2 [11].
In this study, we carried out experiments in order to further characterize the type of inhibition
exerted by D11 on CK2. Interestingly, increasing concentrations of co-substrate (i.e., ATP) tested
with three different concentrations of inhibitor, respectively, resulted in decreased apparent maximum
velocity (Vappmax) and increased apparent KM (KappM) values suggesting a linear mixed-type inhibition
against ATP as can be seen from the Michaelis-Menten plots (Figure 1A). Non-linear least-squares
fits of the curves in Figure 1A to rectangular hyperbolas were used to determine the apparent KM
and Vmax values resulting from the effect of different concentrations of inhibitor. From the estimated
apparent KM and Vmax values we created re-plots for the determination of KI (dissociation constant
for binding of D11 to the free enzyme, 7.7 nM, Figure 1B) and KI′ (dissociation constant for binding of
D11 to the enzyme-substrate complex, 42 nM, Figure 1C).
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Figure 1. Kinetic mechanisms of CK2 inhibition. (A) Michaelis-Menten curves showing how velocity 
varies over a range of substrate concentrations for three different concentrations of inhibitor. The 
velocity equation relative to the hyperbolic curves of the graph for mixed inhibition is shown above 
the plots. I: inhibitor (D11), KI: dissociation constant for binding of inhibitor to free enzyme, KI′: 
dissociation constant for binding of inhibitor to substrate-bound enzyme. (B) Apparent KM (KMapp) re-
plotted against varying concentrations of inhibitor (used for the calculation of KI). (C) Reciprocal 
apparent Vmax (1/Vmaxapp) re-plotted against varying concentrations of inhibitor (employed for the 
calculation of KI′). The reaction rate is expressed in pmol/min/ng. Experiments were repeated three 
times. 
We previously showed that viability of the human glioblastoma cell line U-87 MG decreased by 
50% following treatment with 25 μM D11 for 24 h [12]. Here, we carried out a cell cycle analysis by 
flow cytometry and asked the question whether D11 treatment induced cell death (Figure 2). Cells 
were treated with increasing concentrations of D11 for 24 h (Figure 2A, left bar graph) and 48 h 
(Figure 2A, right bar graph), respectively. As compared to control experiments, cells were not 
significantly affected by treatment with 50 μM D11 for 24 h (Figure 2A, left bar graph). However, 
incubation of cells with 50 μM D11 for 48 h was accompanied by a modest increase in the percentage 
of cells in sub-G1 phase indicative of cells that have undergone DNA degradation (Figure 2A, right 
bar graph). Next, Western blot analysis was carried out in order to determine the type of cell death. 
As shown in Figure 2B, treatment with 50 μM D11 for 48 h was necessary for inducing cleavage of 
full-length PARP, caspase 9 and caspase 3. However, a shorter incubation time (i.e., 24 h) was 
sufficient to induce increased LC3-II signal as compared to control cells suggesting induction of 
autophagy, in a time and concentration-dependent manner. The staining of cells with acridine orange 
Figure 1. Kinetic mechanisms of C 2 i i iti . i li - e te curves showing how velocity
varies over a r nge of sub trate concentrations for three diff rent concentrations of i hibitor. The velocity
equation r lative to the hyperbolic curves of the graph for mixed inhibition is shown above the plots.
I: inhibit r (D11), KI: dissociation constant for bindi g of inhibitor to free enzyme, KI′: dissociation constant
for bind ng of inhibitor t substrate-bound enzyme. (B) Appare t KM (KMapp) re- lott d against varying
concentrations of inhibitor (used for the calculation of KI). (C) Reciprocal apparent Vmax (1/Vmaxapp)
re- lott d against varying concentrations of inhibitor (employed for the calculati n of KI′). The reaction
rate is expressed in pmol/min/ng. Experiments were repeated three times.
We previously showed that viability of the human glioblastoma cell line U-87 MG decreased by
50% following treatment with 25 µM D11 for 24 h [12]. Here, we carried out a cell cycle analysis by flow
cytometry and asked the question whether D11 treatment induced cell death (Figure 2). Cells were
treated with increasing concentrations of D11 for 24 h (Figure 2A, left bar graph) and 48 h (Figure 2A,
right bar graph), respectively. As compared to control experiments, cells were not significantly affected
by treatment with 50 µM D11 for 24 h (Figure 2A, left bar graph). However, incubation of cells
with 50 µM D11 for 48 h was accompanied by a modest increase in the percentage of cells in sub-G1
phase indicative of cells that have undergone DNA degradation (Figure 2A, right bar graph). Next,
Western blot analysis was carried out in order to determine the type of cell death. As shown in
Figure 2B, treatment with 50 µM D11 for 48 h was necessary for inducing cleavage of full-length
PARP, caspase 9 and caspase 3. However, a shorter incubation time (i.e., 24 h) was sufficient to induce
increased LC3-II signal as compared to control cells suggesting induction of autophagy, in a time and
concentr tion-depende t manner. The staini g of cells with acridine orang (Figure 2C), a vital dye,
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which accumulates in acidic compartments emitting red fluorescence indicative of autophagic vacuoles
formation, further confirmed results reported above.
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Figure 2. Anti-proliferative effects of D11 in human glioblastoma cells. (A) Flow cytometry analysis
of cells vehicle-treated (Control, 0.1% DMSO) or incubated with increasing concentrations of D11 for
24 h (left bar graph) and 48 h (right bar graph), respectively. The relative amount of cells in the various
phases of the cell cycle is shown in percentage. (B) Cells were treated as described above. Whole cell
lysate was analyzed by western blot employing antibodies directed against the indicated proteins.
β-actin detection was carried out as control for equal loading. (C) Flow cytometry analysis of cells
treated as described in (A) stained with acridine orange for the determination of autophagic vacuoles
formation. Number of red-positive cells is expressed in percentage. Experiments were performed three
times obtaining similar results.
2.2. D11 Treatment Abolishes HIF-1α Transcriptional Activity and Results in Increased Activation of
Autophagy under Hypoxia in Glioblastoma Cells
HIF-1 is a heterodimeric transcription factor consisting of two subunits; i.e., HIF-1β, which is
constitutively expressed, and HIF-1α whose expression is regulated by oxygen levels. Stabilization of
HIF-1α occurs under hypoxic conditions and leads to translocation into the nucleus where it induces the
transcription of numerous genes as part to the hypoxia response (reviewed in [10]). Tumor suppressor
genes encoding proteins such as the Von Hippel-Lindau (VHL) and PTEN have been reported to
inhibit HIF-1α function. In particular, PTEN has been demonstrated to inhibit HIF-1α stabilization
by antagonizing the PI3K pathway [6,19,20]. As U-87 MG cells contain mutant PTEN [21], we asked
whether D11-mediated inhibition of CK2 resulted in HIF-1α destabilization and if this event had
implications for the activation of cell death. To accomplish this, we compared the levels of expression
of HIF-1α in cells treated with vehicle (0.1% DMSO), D11 or other known CK2 inhibitors under
normoxia and hypoxia, respectively (Figure 3A). Under hypoxic conditions, U-87 MG cells showed
induction of HIF-1α. Moreover, treatment with the indicated compounds resulted in inhibition of
endogenous CK2 to various extents as indicated by decreased phosphorylation of NF-κB/p65 at S529
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a known CK2 phosphorylation site [22]. Results shown in Figure 3A indicate that cell incubation with
D11, E9 or CX-4945 resulted in destabilization of HIF-1α indicated by the reduced HIF-1α protein
band intensity as compared to control experiments. Next, we analyzed whether D11 affected HIF-1α
transcriptional activity employing a Luciferase reporter assay (Figure 3B).
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Figure 3. Stabilization and transcriptional activity of HIF-1α under hypoxia is impaired in cells
treated with D11. (A) U-87 MG cells were treated with vehicle (Control), 50 µM D11, 50 µM E9 or
20 µM CX-4945 for 24 h under normoxia (N) and hypoxia (H), respectively. Whole cell lysate from
cells treated as shown in the figure was subjected to western blot analysis and the expression and
phosphorylation levels of the indicated proteins were analyzed. β-actin detection was used as loading
control. Experiments were performed three times obtaining similar results. (B) Cells were transfected
with a control plasmid (p-Luc) or a plasmid containing HIF-1α response element (p-HIF-Luc). 24 h
from transfection, cells were added vehicle (0.1% DMSO) or 50 µM D11 and incubated under normoxic
(N) or hypoxic (H) condition for the subsequent 24 h. HIF-1α transcriptional activity was analyzed
employing a luciferase reporter gene assay. HIF-1α activity was measured testing the ability of the
transcription factor to bind the HIF-1α response element that controls the expression of the luciferase
reporter gene. HIF-1α transcription activity is expressed in counts/s (CPS). Experiments were repeated
twice in triplicates obtaining similar results. * p < 0.005, ** p < 0.0001.
Cells were transfected with p-HIF1-Luc reporter vector able to express firefly luciferase under
the control of a HIF-1-response element (p-HIF-Luc). As a negative control, cells were transfected
with a vector lacking the specific response element (p-Luc). The transcription activity of HIF-1α
increased dramatically under hypoxic conditions (i.e., 443128 CPS) as compared to its activity under
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normoxia (i.e., 98746 CPS). Upon treatment with 50 µM D11 for 24 h, luciferase activity induced by
HIF-1α stabilization was drastically reduced (i.e., 31917 CPS) under hypoxia supporting the notion
that D11 impairs the transcriptional activity of HIF-1α. In order to determine whether destabilization
of HIF-1α had an influence on cell death, cells were incubated with D11 under normoxia and hypoxia,
respectively. As shown in Figure 4, the exposure of cells to hypoxia did not result in higher PARP
cleavage, however, it resulted in higher levels of autophagy induction as compared to cells grown
under normoxia. Experiments carried out in the absence or presence of bafilomycin A1, which blocks
fusion of autophagosomes with lysosomes, revealed that D11 treatment leads to enhanced autophagic
flux indicated by a further increase in LC3-II levels in the presence of bafilomycin A1.
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Figure 4. D11-mediated destabilization of HIF-1α under hypoxia is accompanied by higher levels of
autophagy. Cells were incubated with 0.1% DMSO, 50 µM D11 alone or in combination with 100 nM
bafilomycin A1 (Baf) under normoxia and hypoxia, respectively. Cells were treated with D11 for 24 h
while bafilomycin A1 was added in the last 6 h of incubation time. Proteins were visualized by probing
the western blot membranes with antibodies against the indicated proteins.
2.3. Cell Incubation with D11 Results in Altered Gene Expression Profile Induced by Hypoxia
Stabilization of HIF-1α in the absence of oxygen stimulates the expression of numerous
hypoxia-response genes that promote the survival of cancer cells in an unfavorable environment.
In order to investigate differential mRNA expression in glioblastoma cells resulting from D11 treatment
under hypoxic conditions, we analyzed the expression of 84 genes that respond to low oxygen
levels using the human hypoxia-signaling pathway RT2 Profiler PCR array. Cells were grown
under normoxic or hypoxic conditions for 24 h and incubated either with vehicle (0.1% DMSO)
or 50 µM D11 for the same length of time. Based on scatter plot analysis (Figure 5B, upper plot),
a number of known HIF-1α-target genes were found up-regulated in control cells in response to
hypoxia (CTH vs. CTN, fold-change ≥ 2, Table 1). In particular, the strongest up-regulation was
observed in the case of angiopoietin-like 4 (ANGPTL4), Bcl2/adenovirus E1B 19 kDa interacting
protein 3 (BNIP3), carbonic anhydrase IX (CA9), DNA-damage-inducible transcript 4 (DDIT4),
coagulation factor III (F3), insulin-like growth factor binding protein 3 (IGFBP3), lysyl oxidase
(LOX), matrix metallopeptidase 9 (MMP9), N-myc downstream regulated 1 (NDRG1), solute carrier
family 2 member 1 (SLC2A1) and vascular endothelial growth factor A (VEGFA). In contrast, when
we analyzed the genes that showed differential expression under hypoxic conditions and looked
at their up- or down-regulation in response to D11 treatment (i.e., D11H vs. CTH), we noticed
that most of them failed to become up-regulated or appeared to be partially down-regulated
(Figure 5B, lower plot and Table 1). However, strong down-regulation was observed in the case of F3,
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (PFKFB4), solute carrier family 16 member 3
(SLC16A3) and VEGFA (Table 1). HIF-1α protein expression levels increased under hypoxic conditions
(Figure 5A). Conversely, consisting with data reported earlier [23,24], up-regulation of HIF-1α was
not accompanied by a change in its mRNA levels in cells exposed to hypoxia as compared to cells
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incubated under normoxia. Interestingly, D11 treatment resulted in decreased expression of HIF-1α
protein but not mRNA levels under hypoxia (results not shown) suggesting alternative D11-mediated
mechanisms of regulation of HIF-1α.
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Figure 5. Genes differentially expressed in response to hypoxia and D11 treatment. (A) Western blot
analysis of whole cell lysate from cells incubated with 0.1% DMSO or 50 µM D11 for 24 h under
normoxia and hypoxia, respectively. Western blot membranes were employed for the detection of
HIF-1α and β-actin expression levels, respectively. (B) Scatter plot of changes of expression of genes in
glioblastoma cells. Upper panel: changes of gene expression between cells incubated under normoxia
(control) and cells incubated under hypoxia for 24 h. Lower panel: changes of gene expression in the
presence or absence of D11 under hypoxic conditions. The fold regulation cut-off (red dashed line) was
set on 2.
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Table 1. Gene expression analysis.
Protein Gene Symbol Fold-Change Fold-Change
CTH vs. CTN D11H vs. CTH
Adrenomedullin ADM 4.358 1.226
Angiopoietin-like 4 ANGPTL4 7.646 −7.888
Ankyrin repeat domain 37 ANKRD37 2.880 −2.106
Basic helix-loop-helix family member e40 BHLHE40 3.229 −2.275
Bloom syndrome, RecQ helicase-like BLM −1.904 −1.549
Bcl2 interacting protein 3 BNIP3 5.984 1.282
Bcl2 interacting protein 3-like BNIP3L 3.364 −1.058
Carbonic anhydrase IX CA9 10.768 −2.924
Cyclin G2 CCNG2 3.367 2.445
DNA-damage-inducible transcript 4 DDIT4 7.233 −4.314
Egl nine homolog 1 (C. elegans) EGLN1 1.953 −2.032
Early growth response 1 EGR1 −2.474 54.951
Erythropoietin EPO 2.150 1.275
ERO1-like (S. cerevisiae) ERO1A 2.033 −1.566
Coagulation factor III F3 5.802 −41.328
Glucan branching enzyme 1 GBE1 2.523 −2.082
Glycogen synthase GYS1 2.051 −2.645
Hypoxia inducible factor 3 α subunit HIF3A 3.719 −3.992
Hexokinase 2 HK2 3.152 1.100
Insulin-like growth factor binding protein 3 IGFBP3 67.054 −11.170
Lactate dehydrogenase A LDHA 2.602 −2.361
Lectin, galactoside-binding, soluble, 3 LGALS3 2.363 −2.141
Lysyl oxidase LOX 5.199 −4.730
Macrophage migration inhibitory factor MIF 1.986 −1.040
Matrix Metallopeptidase 9 MMP9 6.044 −2.535
MAX interactor 1 MXI1 4.017 −1.462
N-myc downstream-regulated 1 NDRG1 15.150 −3.611
Ornithine decarboxylase 1 ODC1 −2.231 11.551
Prolyl 4-hydroxylase, α 1 P4HA1 3.362 1.053
Pyruvate dehydrogenase kinase PDK1 2.946 −1.522
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 PFKFB3 2.394 1.146
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 PFKFB4 3.304 −14.057
Phosphofructokinase, liver PFKL 2.452 −2.309
Placental growth factor PGF 2.242 2.089
Phosphoglycerate kinase 1 PGK1 3.159 −1.581
Plasminogen activator, urokinase PLAU −2.926 1.674
Serpin peptidase inhibitor, clade E member 1 SERPINE1 1.911 1.744
Solute carrier family 16 member 3 SLC16A3 2.454 −4.346
Solute carrier family 2 member 1 (GLUT1) SLC2A1 5.890 −1.162
Solute carrier family 2 member 3 (GLUT 3) SLC2A3 2.462 2.460
Thioredoxin interacting protein TXNIP 3.422 1.559
Vascular endothelial growth factor A VEGFA 5.367 −11.028
CTH: control cells (vehicle-treated) grown under hypoxia, CTN: control cells (vehicle-treated) grown under
normoxia, D11H: D11-treated cells under hypoxia.
3. Discussion
Hypoxia is a critical condition for many types of cancers because it signals adaptation of cells
to an anaerobic environment achieved by induction of gene expression. Limited oxygen diffusion is
frequently observed in the glioma microenvironment and it has been associated with poor prognosis,
increased metastasis, angiogenesis and resistance to radio- and chemotherapy. The stabilization of
HIF-1α transcription factor is one of the most critical events occurring under hypoxia, as it is the
primary factor responsible for many of the effects observed in aggressive tumors. Hence, it is not
surprising that HIF-1α has become an important target for drug development in recent years as
blocking HIF-1α activity would help starve growing tumors of oxygen and nutrients.
Our in vitro data show that treatment of cells with D11, a small-molecule inhibitor of protein
kinase CK2, results in destabilization of HIF-1α protein under hypoxic conditions. Similar results were
also reported in the case of other CK2 inhibitors (i.e., E9, CX-4945 and quercetin, [25]). It has been
demonstrated that HIF-1α mRNA levels do not vary under hypoxic conditions [23,24]. Accordingly,
the analysis of gene expression data did not reveal any significant differences in the expression
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of HIF-1α in cells growing under normoxia or exposed to hypoxia in the absence and presence of
D11, respectively, suggesting that regulation of HIF-1α expression occurs at the post-translational
level. Apart from CK2 inhibitors, other compounds can induce HIF-1α destabilization. The small
molecule inhibitor YC-1 [3-(-5′-hydroxymethyl-2′-uryl)-1-benzylindazole] was shown to reduce HIF-1α
levels and xenograft growth of various human tumors through mechanisms yet to be elucidated [26].
Under hypoxic conditions, HIF-1α stability is dependent on its interaction with the chaperone HSP-90
and cell incubation with the HSP-90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG)
has been shown to induce HIF-1α degradation in a VHL-independent manner [27–29].
The activity of chaperone proteins is dependent on their interaction with co-chaperone proteins
and co-activators [30]. Compelling evidence has indicated that CK2-mediated phosphorylation
of the co-chaperone CDC37 is essential for stabilization of HSP-90-CDC37 heterocomplex and its
interaction with client protein kinases (reviewed in [31]). Hence, HIF-1α degradation observed in cells
incubated with D11 under hypoxia might result from disruption of HSP-90-CDC37 interaction as cell
treatment with this inhibitor has been reported to reduce CDC37 phosphorylation [11] and destabilize
HSP-90-CDC37 heterocomplex [12].
Induction of autophagy was found significantly enhanced in U-87 MG cells following incubation
with D11 for 24 and 48 h, respectively. At presence, it is not possible to assert whether induction
of autophagy constitutes a stress adaptation conferring cytoprotection or an alternative cell death
mechanism. However, the fact that PARP cleavage becomes visible after 48 h of incubation with D11
does not exclude that autophagy might develop as a primary response to stress stimuli in the first 24 h
of incubation with the inhibitor and triggers apoptosis to kill cancer cells following a longer incubation
time. This sequence of events has been shown to occur in the case of CD4/CXCR4-expressing T cells
after binding of HIV-1 envelope proteins [32].
The hypoxic response includes the induction of a variety of pro-angiogenic genes. Specifically,
the gene expression analysis identified strong up-regulation of ADM, ANGPTL4 and VEGFA (Table 1).
Conversely, the expression of these genes was found down-regulated in cells treated with D11
under hypoxia suggesting that D11 antagonizes the transcription of pro-angiogenesis genes through
mechanisms that may be dependent or not on HIF-1α expression status.
Under hypoxic conditions, cells use glycolysis as a primary mechanism of ATP production.
This metabolic switch is encouraged by stabilization of HIF-1α, which induces the expression of
genes involved in metabolic adaptation including glucose uptake and the glycolytic pathway. Indeed,
the expression of several of the genes involved in glucose metabolism (i.e., HK1 and -2, GLUT1 and
-3, GYS1, LDHA, PDK1, PFKFB3 and -4) was found up-regulated under hypoxia and marginally
or largely down-regulated when cells were additionally treated with D11 (Table 1). This suggests
that D11 treatment severely deprives cancer cells of oxygen and nutrient supply by suppressing the
oxygen-independent metabolic pathway.
There is ample evidence that changes in metabolic activity observed in cancer cells influence
the intracellular pH. Glycolysis is thought to be the major mechanism responsible for lowering
the pH. Evidence indicates that the activity of carbonic anhydrase (CA9), which converts carbon
dioxide and water to carbonic acid, is strongly induced in hypoxia contributing to low pH of the
tumor. High expression levels of CA9 have been associated with poor prognosis [33]. Our results are
consistent with previous studies investigating gene expression in response to hypoxia. Accordingly, the
expression of CA9 was found largely up-regulated under hypoxia (i.e., 10.768 fold-change as compared
to CTN), however, treatment of cells with D11 resulted in a −2.924 fold-change of CA9 with respect to
CTH suggesting that D11 compromises another important adaptation of tumor cells which seems to be
essential for promoting tumor invasion. In this respect, it has been shown that many proteases are
activated under acidic conditions promoting tumor invasion of surrounding tissue [34].
N-myc downstream-regulated gene 1 (NDRG1) is a member of the NDRG gene family, which
is expressed ubiquitously in tissues in response to various stress conditions including cellular
differentiation, tumor progression and metastasis, DNA damage and hypoxia. Expression of NDRG1
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in response to low oxygen concentrations is HIF-1α-regulated, as induction of NDRG1 does not occur
in HIF-1α−/− mouse embryo fibroblasts. However, an increase in intracellular Ca2+ seems to be
sufficient to induce NDRG1 mRNA expression in HIF-1α-deficient cells under hypoxia (reviewed
in [35]). A number of research groups have shown that NDRG1 over-expression decreases tumor
growth, reduces invasion and suppresses metastasis [36,37]. However, Salnikow et al., demonstrated
that NDRG1 expression is dramatically increased in aggressive prostate cancer cells [38]. In our
study, NDGR1 expression was found elevated (15.150 fold-change) under hypoxia while additional
incubation with D11 resulted in a −3.6 fold-change (Table 1). There appears no clear connection
in the effect of Ca2+ and HIF-1α on NDRG1 induction in cancer cells. Hence, it is likely that when
oxygen levels decrease, NDRG1 induction is linked to intracellular mechanisms somewhat unrelated
to metastasis and cell growth yet to be elucidated.
Finally, analysis of the gene expression array also revealed that two hypoxia-responsive genes
involved in cell adhesion, invasion and vascular remodeling (i.e., ANKRD37 and MMP9) were found
largely down-regulated in D11 treated cells. Suppression of ANKRD37 and MMP9 expression may
explain, at least in part, D11-mediated impaired migration of glioblastoma and pancreatic cancer
cells reported previously [12] and indicates that treatment of glioblastoma cells with this compound
compromises cell migration and invasion by suppressing the expression of proteins that are crucial in
the metastatic process.
4. Materials and Methods
4.1. Cell Culture and Hypoxia
The human glioblastoma cell line U-87 MG was purchased from the American Type Culture
Collection (ATCC, Rockville, MD, USA) and cultivated at 37 ◦C under a 5% CO2 atmosphere
in Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen, Taastrup, Denmark) supplemented
with 10% fetal bovine serum (FBS, Biochrom AG, Berlin, Germany). Cells were treated with
4-[(E)-(fluoren-9-ylidenehydrazinylidene)-methyl] benzoic acid (referred to as E9, [25]), D11 (both from
DTP, NIH/NCI, Rockville, MD, USA) or CX-4945 (Selleck Chemicals, Houston, TX, USA) as indicated in
the figure legends. Hypoxia (1% O2) experiments were carried out according to [39]. Where indicated,
cells were treated with 100 nM bafilomycin A1 (Sigma-Aldrich, Brøndby, Denmark) for 6 h.
4.2. Radioactive Kinase Assay
The kinase activity of human recombinant CK2α1−3352β2 was determined in the presence of the
CK2 synthetic peptide RRRADDSDDDDD (100 µM), increasing concentrations of ATP (i.e., 5, 10, 50,
100, 200, 300 and 400 µM) and inhibitor as indicated in the figure legends and essentially as described
elsewhere [40]. Kinetic parameters (i.e., KM and Vmax) were calculated using GraphPad Prism version
6.0 computer software (GraphPad Software Inc., San Diego, CA, USA) based on the Michaelis-Menten
plots. KI values were determined from the re-plots where apparent KM values and apparent Vmax
values were plotted against inhibitor concentration, respectively.
4.3. Cell Cycle Analysis by Flow Cytometry
Propidium iodide staining of cells and flow cytometry analysis were performed essentially as
previously described [41]. Autophagy was analyzed by staining cells with 1 µg/mL acridine orange
(Sigma-Aldrich) for 15 min prior harvesting by trypsinization and flow cytometry analysis.
4.4. Preparation of Whole Cell Lysate, Western Blot Analysis and Antibodies
Western blot analysis of whole cell lysate was performed as reported in [41]. The following
primary antibodies were employed in the study: rabbit monoclonal anti-NF-κB/RelA and rabbit
monoclonal anti-LC3 (both from Cell Signaling Technology, Beverly, MA, USA); mouse monoclonal
anti-β-actin (Sigma-Aldrich); rabbit polyclonal anti-phospho-NF-κB/p65 (S529, Abcam, Cambridge,
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MA, USA); mouse monoclonal anti-PARP and mouse monoclonal anti-HIF-1α (both from BD
Biosciences, San Jose, CA, USA).
4.5. Luciferase Reporter Assay
Determination of the transcriptional activity of HIF-1α was carried out with whole cell lysate
(10 µg) from cells transfected with a luciferase reporter vector (Panomics, Affymetrix, Santa Clara, CA,
USA) carrying a control sequence or HIF-1α consensus element. Transfection of cells was performed
with Lipofectamine 2000 according to the manufacturer’s (Invitrogen) guidelines. After 24 h from
transfection, cells were added 50 µM D11 for additional 24 h before harvesting. Cells were grown under
normoxia or hypoxia in the last 24 h of incubation time as indicated in the figure legends. Determination
of luciferase activity was performed employing the Luciferase Assay System kit (Promega, Stockholm,
Sweden) according to the manufacturer’s recommendations. Luminescence was measured with a
Perkin Elmer Victor Light 1420 luminescence counter (Perkin Elmer, San Diego, CA, USA).
4.6. Gene Expression Analysis by Quantitative RT-PCR Array
Total RNA samples preparation from cells treated as described in the figure legends was
carried out by phenol-chloroform extraction and subsequent silica-membrane-based purification
in combination with on-column DNAse digestion with the miRNeasy kit (Qiagen, Hilden, Germany)
following the manufacturer’s instructions. RNA integrity was assessed by agarose gel analysis.
The cDNA was prepared using the RT2 First strand kit (Qiagen). The expression analysis of 84 genes
associated with hypoxia was carried out with the Qiagen RT2 Profiler PCR array according to
the manufacturer’s guidelines in 96-well plates with a StepOnePlusTM real-time cycler (Applied
Biosystems, Nærum, Denmark). Data were normalized to five housekeeping genes included in the kit.
Normalized data were analyzed using the ∆∆Ct method with the equation ∆∆Ct = ∆Ct (experimental
sample group) − ∆Ct (control group), and the fold-change was calculated based on ∆∆Ct with 2−∆∆Ct
for positive changes or with −1/2−∆∆Ct for negative changes [42,43].
4.7. Statistical Analysis
Statistical significance of differences between means of two groups was determined by the
two-tailed t-test (student’s t-test). The levels of significance are indicated in the figure legends.
5. Conclusions
Hypoxic adaptation is a frequently occurring event in tumor growth and it is associated to a
more invasive phenotype and resistance to conventional treatment. This has been unequivocally
demonstrated in the case of brain cancer. Hence, the identification of new therapeutic strategies
targeting HIF-1α represents an attractive alternative option to the current treatment modalities.
Our data show that incubation of glioblastoma cells with D11 results in rapid HIF-1α destabilization
and impaired transcriptional activity. Gene expression analysis show that reduced HIF-1α expression
in response to D11 treatment is accompanied by down-regulation of genes involved in angiogenesis,
glucose metabolism, pH regulation, cell adhesion and invasion. Collectively, these results suggest
that the combination of D11, or more potent derivatives, with existing treatments may prove to be an
effective strategy in the clinics for the cure of brain cancer in the future.
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